Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Documented diagnosis of Crohn's Disease (CD) for at least 3 months prior to screening, including ileal, colonic, or ileo-colonic disease distribution
Must have had an inadequate response, loss of response, or intolerance to 1 or more of the standard treatments
Must have active moderate to severe CD
Men and women must agree to follow specific methods of contraception, if applicable
You may not be if
Severe or fulminant colitis that is likely to require surgery or hospitalization
Presence of a diagnosis of alternative forms of colitis (infectious, inflammatory including ulcerative colitis, malignant, toxic, indeterminate, etc.) other than Crohn's Disease
Previous exposure to BMS-986165 in any study
Any major illness/condition or evidence of an unstable clinical condition (eg, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, immunologic, psychiatric, or local active infection/infectious illness) that, in the investigator's judgment, will substantially increase the risk to the participant
Clareo Health | An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease
